Gen Surg SAQs · endocrine
Small pancreatic tumour verdicts, insulinoma localisation ladders, and gastrinoma cure operations
Fellowship SAQ on small pancreatic NET surveillance-versus-resection verdicts with node-risk scoring, insulinoma localisation and parenchyma-sparing ladders, and gastrinoma duodenotomy cure operations.
On this page
Study tools
Target exams
Write your answer
Saved on this device. No marking — you are the marker.
(A) Surgery is default above one centimetre and selective below it: pooled pancreatic analysis gives operative mortality hazard 0.30 with 5-year survival 77% against 46%, yet sub-centimetre disease shows comparable survival either way.[10] Surveillance is defensible for the small asymptomatic lesion — five-study review at 540 patients with up to half showing growth, one in seven crossing to resection, and zero disease-related deaths on watch.[11] The database sharpens it: 2,004 localised well-differentiated tumours with resection improving survival above one centimetre, and age, comorbidity, stage, location and resection as independent prognostics.[12] Score her nodes before watching: the 1-to-7 location-plus-proliferation score bands low, intermediate and high risk — distal low-proliferation watches, proximal higher-proliferation resects with nodes.[13]
(B) Expect a 10-month median symptom-to-diagnosis delay, then localise with everything: CT, MRI and endoscopic ultrasound combined, ultrasound most sensitive with MRI and ultrasound each rescuing CT-negative tumours; spare parenchyma in suitable cases with formal resection for vessel, duct or malignancy concern.[16] Approach it minimally invasively when localised and feasible: 71-patient enucleation comparison with shorter minimally invasive times excluding conversions, equivalent late complications, 5.6% functional recurrence at 75 months, and no disease recurrence after R1 resection.[15]
(C) Open every sporadic duodenum: routine duodenotomy finds gastrinoma in 98% against 76% with duodenal primaries at 62% against 18%, lifting immediate cure to 65% against 44% and long-term cure to 52% against 26%.[17] Counsel honestly from the 10-year protocol: 78% found and resected, 11% morbidity without deaths, half the disease-free recurring by five years, yet excellent overall survival against 20% once metastatic at presentation — most found, about one-third cured.[18]
References8ShowHide
- [10]Khajeh E, et al. Surgical Versus Nonsurgical Management of Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis. Ann Surg Oncol, 2025.PMID 40705264
- [11]Partelli S, et al. Systematic review of active surveillance versus surgical management of asymptomatic small non-functioning pancreatic neuroendocrine neoplasms. Br J Surg, 2017.PMID 27706803
- [12]Assi HA, et al. Surgery Versus Surveillance for Well-Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11-Year Analysis of the National Cancer Database. Oncologist, 2020.PMID 32043766
- [13]Lopez-Aguiar AG, et al. The conundrum of < 2-cm pancreatic neuroendocrine tumors: A preoperative risk score to predict lymph node metastases and guide surgical management. Surgery, 2019.PMID 31072670
- [15]Belfiori G, et al. Minimally Invasive Versus Open Treatment for Benign Sporadic Insulinoma Comparison of Short-Term and Long-Term Outcomes. World J Surg, 2018.PMID 29691623
- [16]Andreasi V, et al. Diagnostic work-up and surgical management of insulinoma: A retrospective analysis from a tertiary referral center. J Neuroendocrinol, 2023.PMID 37915303
- [17]Norton JA, et al. Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases, or survival in patients with Zollinger-Ellison syndrome? Ann Surg, 2004.PMID 15082965
- [18]Norton JA, et al. Curative resection in Zollinger-Ellison syndrome. Results of a 10-year prospective study. Ann Surg, 1992.PMID 1531004